Assertio Holdings, Inc. (ASRT)
Assertio Holdings, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Lake Forest, IL, US. The stock last traded at $23.50, up 0.00% on the session, giving a market capitalisation of $151.9M. On trailing twelve-month figures it carries a trailing P/E of -4.24, a net margin of -34.9%. Its beta of 0.53 implies it has historically moved less than the broad market.
Assertio Holdings, Inc. is a specialized pharmaceutical company focused on developing and commercializing therapeutic solutions across key medical domains, including neurology, hospital care, and pain and inflammation management. Among its portfolio, Assertio offers INDOCIN, available as both an oral solution and a suppository. This medication addresses conditions such as moderate to severe rheumatoid arthritis (including acute flare-ups), ankylosing spondylitis, osteoarthritis, acute painful shoulder, and gouty arthritis. The company's offerings also encompass CAMBIA, an NSAID specifically formulated to alleviate symptoms associated with migraine headaches, including nausea, light sensitivity (photophobia), and sound sensitivity (phonophobia). Zipsor, another NSAID, is indicated for managing mild to moderate acute pain. For more significant short-term pain relief, SPRIX, also an NSAID, provides analgesia comparable to opioid-level treatments for moderate to moderately severe pain. Rounding out its product line is Otrexup, a prescription methotrexate delivered via a convenient single-dose auto-injector. This therapy targets severe, active rheumatoid arthritis in adults and active polyarticular juvenile idiopathic arthritis in pediatric patients. Initially incorporated as Assertio Therapeutics, Inc. in 1995, the organization rebranded to Assertio Holdings, Inc. in May 2020 and maintains its corporate headquarters in Lake Forest, Illinois.
Assertio Holdings, Inc. is most often compared with the following Healthcare names: